Mera Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended July 31, 2021
September 16, 2021 at 04:05 pm EDT
Share
Mera Pharmaceuticals, Inc. announced unaudited earnings results for the third quarter and nine months ended July 31, 2021. For the quarter, the company reported operating loss of $1,365 against $1,395 a year ago. Net loss was $1,365 against $1,395 a year ago.
For the nine months, the company reported operating loss of $8,889 against $4,185 a year ago. Net loss was $8,889 against $4,185 a year ago.
Mera Pharmaceuticals, Inc. is a marine biotechnology company. The Company focuses on photobioreactor technology and owns intellectual property dedicated to the culture of microalgae for biofuel or nutriceutical production. The Company manufactures natural astaxanthin from Haematococcus pluvialis microalgae. Through its research and development, the Company has formulated AstaFactor, an astaxanthin supplement with antioxidant and anti-inflammatory activity, which is available in three formulations, such as rejuvenating formula, sports formula and salmon essentials, such as natural astaxanthin combined with a blend of fish and salmon oil. The Company also produces sea salt products, such as gourmet salt and nigari. The gourmet salt includes Hawaiian Furikake, Hawaiian Furikake refillable grinder, Kona Sea Salt, Kona Sea Salt flake salt case, Kona Sea Salt grinder and Kona Sea Salt grinder case. The Company offers nigari in sizes ranging from one gallon to 250 gallons.
MERA PHARMACEUTICALS, INC. 
